5-Amino-1MQ: A Research Guide to the NNMT Inhibitor

• DateJuly 9, 2026

Quick answer: 5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is frequently grouped with research peptides because it is supplied and studied in the same laboratory contexts, but chemically it is a small molecule, not a chain of amino acids. In preclinical (animal and cell) studies, inhibiting NNMT has been associated with changes in NAD+ levels, fat-cell metabolism, and cellular energy expenditure.

5-Amino-1MQ has become one of the most-discussed compounds in metabolic research. Much of the online content about it overstates what the science shows or misclassifies the molecule entirely. This guide takes a research-first approach: what 5-Amino-1MQ actually is, the enzyme it targets, what preclinical studies have and have not demonstrated, how it is handled in the lab, and the questions researchers ask most. You can explore the compound itself on the Project Amino 5-Amino-1MQ product page.
Everything below is for in-vitro laboratory and research use only. See the notice at the end of this article.

What is 5-Amino-1MQ?

5-Amino-1MQ, formally 5-amino-1-methylquinolinium, is a synthetic small molecule developed as a selective, cell-permeable inhibitor of the NNMT enzyme. In research settings it is studied for how NNMT inhibition influences NAD+-related metabolism, fat-cell (adipocyte) biology, and cellular energy balance.
Its single, well-defined mechanism — selective NNMT inhibition — is what sets it apart from most other metabolic research compounds, which act through broader or less specific pathways.

Is 5-Amino-1MQ actually a peptide?

Strictly speaking, no. A peptide is a short chain of amino acids linked by peptide bonds. 5-Amino-1MQ is a small-molecule compound — a modified quinolinium structure — not an amino-acid chain. It shows up under the “peptide” umbrella mainly because body-composition and longevity research content tends to group metabolic research compounds together, and because it is sold, stored, and studied alongside genuine research peptides.
The accurate framing, and the one Project Amino uses, is this: 5-Amino-1MQ is commonly searched in peptide-research contexts, but chemically it is a small-molecule NNMT inhibitor. That distinction matters for anyone reading the primary literature, because studies index it as a small molecule, not a peptide therapeutic.

How does 5-Amino-1MQ work? The NNMT and NAD+ connection

To understand the compound, you have to understand the enzyme it blocks.

NNMT (nicotinamide N-methyltransferase) is an enzyme involved in the methylation of nicotinamide, a form of vitamin B3. This reaction sits at the crossroads of two important cellular systems: the NAD+ salvage pathway (which supplies the coenzyme cells use for energy production and DNA repair) and the SAM methyl-donor cycle.

The research hypothesis behind 5-Amino-1MQ is straightforward: by selectively inhibiting NNMT, the compound may shift the balance of nicotinamide, NAD+, and methyl-donor metabolism inside the cell. In one frequently cited 2018 study, NNMT inhibitors reduced intracellular 1-methylnicotinamide, increased intracellular NAD+ and SAM, and suppressed lipogenesis (fat synthesis) in cultured fat cells. Separately, genetic knockdown of NNMT in the fat tissue and liver of mice was reported to protect them from diet-induced obesity and to raise cellular energy expenditure.
An important caveat: the knockdown study used genetic silencing of the enzyme, not 5-Amino-1MQ as a therapy. It supports NNMT as a biologically plausible target, but it is not evidence that the compound produces the same outcomes.

What does the research actually show?

Here is where careful reading matters. The most-repeated claims about 5-Amino-1MQ — reduced fat-cell size, higher NAD+, improved energy metabolism, muscle-stem-cell effects — come predominantly from animal models and cell-culture experiments, not from human clinical trials.

The honest summary: 5-Amino-1MQ has a plausible, well-characterized mechanism and encouraging preclinical data, but demonstrating clinical benefit would require human outcome data, dose-response studies, safety monitoring, and placebo comparison — none of which currently exists at a level that supports therapeutic claims.

How is 5-Amino-1MQ different from research peptides you may know?

Because it is a small molecule rather than a peptide, 5-Amino-1MQ has different physical properties from injectable research peptides. Most notably, it has been reported to be orally bioavailable in some research contexts, which is why it is often supplied in capsule form rather than as a lyophilized powder for reconstitution. Researchers comparing it with compounds like MOTS-C or AOD-9604 should keep that structural difference in mind, since it affects handling, storage, and study design.

Handling and storage in the lab

General good practice for research compounds applies. Keep material sealed, cool, and protected from light and moisture, and follow the specific guidance for the exact product form you have. For capsule and solid forms, store in a cool, dry, dark place as directed. If you also work with lyophilized research peptides that require reconstitution, see the Project Amino guide to reconstituting peptides for sterile-technique and storage fundamentals.

Every compound Project Amino supplies is third-party tested to a minimum 99% purity, and certificates of analysis are available so researchers can verify identity and purity before beginning work.

Updated on: 07/09/2026